healthcare

US still offering the most biotech names

In the wake of recent underperformance, healthcare is entering the new year with compressed valuations just as innovation picks up and a post-COVID reset winds down. That should make for a positive outlook, say Portfolio Managers Andy Acker and Dan Lyons.

UK tipped as best performing region

Though healthcare may have flown under the market’s radar this year, the sector’s attractive valuations and new growth opportunities are not to be overlooked, say Janus Henderson's Portfolio Managers Andy Acker and Dan Lyons.

Managed by Andy Acker and Dan Lyons

'Victims of Covid success'

'Beaten up' since 2021

Peter Hughes

Navigating tailwinds

Seven experts give their opinions